Gilead Sciences, the Foster City, Calif.-based drugmaker under pressure for its hepatitis C drug pricing, announced late last week that longtime CEO John Martin will step down from that role, becoming executive chairman of the company.
Patients with hepatitis C have yet another advanced treatment option, as the Food and Drug Administration on Thursday approved a new once-a-day pill developed by drugmaker Merck.
Pennsylvania state officials Wednesday unveiled a $13 million, six-month program that will offer free hepatitis C antiviral medications for low-income individuals with a dual diagnosis of HIV and hepatitis C. According to the CDC, Pennsylvania had the 10th highest level of new HIV cases in the...
The Massachusetts attorney general's office is investigating whether the makers of a breakthrough treatment for hepatitis C are violating state law by pricing the drug too high.
High prescription drug prices will be a top-tier political issue in 2016 as the expected introduction of many expensive specialty medications to treat chronic conditions threatens to drive up healthcare spending.
The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, U.S. Senate investigators said Tuesday.
Nearly seven-eighths of the country's top healthcare leaders favor the government taking a bigger role in curbing the rising cost of prescription drugs, while nearly all say that the two-year runup in drug prices has hurt their bottom lines.
As more details emerge chronicling the lengths some pharmaceutical firms have gone to to set a premium price on their products, stakeholders are split on whether the government will act on the crisis.
Federal health officials are warning doctors and patients that two hepatitis C drugs from AbbVie can cause life-threatening liver injury in patients with advanced forms of the disease.
The pharmacy benefit management industry has been quietly changing amid healthcare payment reforms and an increasingly fierce debate over drug prices. Now a leadership shuffle at Express Scripts has experts speculating that the days of PBMs as stand-alone companies may be numbered.
Health insurers and pharmacy benefit managers (PBMs) are hoping recent mergers and their growing market clout will help them win steeper drug discounts in their ongoing war with the pharmaceutical industry over specialty drug pricing.
Sovaldi, the $1,000 pill for hepatitis C, is no longer the favorite of patients and doctors. The new leading pill is more expensive, and the number of patients seeking a cure has surged.